Comparative study on the effects of alirocumab versus atorvastatin on cardiac function and lipid profiles in patients with coronary heart disease
LIU Yi
TIAN Junchao
ZHOU Yanji
WANG Hui
FENG Meijing
MA Honghong
ZHANG Kai
Abstract：Objective To investigate the effect of alirocumab versus atorvastatin in improving cardiac function and blood lipid level improvement in patients with coronary artery disease.Methods A prospective study was conducted on 244 patients diagnosed with coronary heart disease at Aerospace Center Hospital from October 2023 to June 2024.The patients were divided into two groups based on their treatment regimen:a control group and an observation group,each consisting of 122 patients.The control group received oral Atorvastatin Calcium Tablets,while the observation group was treated with Alirocumab Injection.The lipid levels,including lipoprotein(a)(Lp(a)),apolipoprotein B(ApoB),apolipoprotein A1(ApoA1),total cholesterol(TC),high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C),and triglyceride(TG),were compared between the two groups.Additionally,parameters such as left ventricular posterior wall thickness(LVPWd),left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),and adverse reactions were also evaluated.Results After treatment completion,the observation group showed significantly lower levels of Lp(a),ApoB,total cholesterol(TC),triglycerides(TG),and LDL-C compared to the control group.Conversely,ApoA1 and HDL-C were significantly higher in the observation group(t=13.254,19.704,17.121,21.059,7.499,17.832,3.194,P<0.05).Additionally,LVPWd and LVEDD were significantly lower,while LVEF was significantly higher in the observation group(t=20.176,26.789,7.654,P<0.05).There was no significant difference in adverse reaction rates between the two groups(P>0.05).Conclusion Alirocumab demonstrated superior efficacy over Atorvastatin in reducing Lp(a),ApoB,TC,TG,and LDL-C levels,while increasing ApoA1 and HDL-C levels.It also improved cardiac structure and function as indicated by reduced LVPWd and LVEDD,as well as increased LVEF.Both treatments had comparable safety profiles.These findings suggest that Alirocumab may offer additional cardiovascular benefits beyond lipid-lowering effects.
Keywords：alirocumabatorvastatincoronary heart diseasecardiac functionblood lipid level
Publication Date：2025-12-31
Online Publishing Date：2026-01-06(First online date of this platform, not the publication date of the document)
Pages：5( 987-991 )